Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Spyre Therapeutics, Inc. Financials Banner

Spyre Therapeutics, Inc. Financials

SYRE Stock Analysis

Page title

Section title

SYRE Income Statement Key Metrics

  • Revenue(TTM)1.04 M
  • Gross Profit(TTM)78,000
  • EBITDA(TTM)-164.31 M
  • Net Income(TTM)-185.98 M
  • EPS Diluted(TTM)-15.45

Decode SYRE's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

SYRE earnings and revenue history

SYRE Return on Equity

See how efficiently SYRE generates profit for it's shareholders.

0%

10
0
100
  1. Poor

  2. Average

  3. Strong

Return on Equity Growth

SYRE's Return on Equity has grown significantly over the past 10 years, increasing by over 23.30%.

SYRE Revenue Growth

See how SYRE has grown it's revenue over the past 10 years.


Revenue Growth

SYRE's revenue has shown poor growth over the past 10 years, increasing by only -18.67%.

SYRE FY, 2023 Revenue Breakdown

See how SYRE converts it's revenue into profit.

SYRE Balance Sheet Health

SYRE Balance Sheet Breakdown 2023

Assets

  1. Long Term Assets

  2. Cash & Equivalents

  3. Inventory

  4. Receivables

  5. Property Plant Equipments

  6. Others

Liabilities

  1. Short Term Debt

  2. Long Term Debt

  3. Account Payables

  4. Others

SYRE financial position analysis

Short Term Liabilities

SYRE's short term assets($342M) can safely cover it's short term liabilities($32M).

Long Term Liabilities

SYRE's short term assets($342M) can safely cover it's long term liabilities($126M).

SYRE Debt to Equity